Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients

Roberto Guariglia,1 Maria Carmen Martorelli,1 Rosa Lerose,2 Donatella Telesca,2 Maria Rita Milella,2 Pellegrino Musto3 1Unit of Hematology and Stem Cell Transplantation, 2Pharmacy Service, 3Scientific Direction, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza, Italy Abstrac...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Guariglia R, Martorelli MC, Lerose R, Telesca D, Milella MR, Musto P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Chemotherapy-induced neutropenia febrile neutropenia granulocyte colony stimulating factors G-CSF pegfilgrastim lipegfilgrastim. Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/1d9aa841d64a4175b0b8db2aa414a927
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1d9aa841d64a4175b0b8db2aa414a927
record_format	dspace
spelling	oai:doaj.org-article:1d9aa841d64a4175b0b8db2aa414a9272021-12-02T06:26:05ZLipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients1177-5491https://doaj.org/article/1d9aa841d64a4175b0b8db2aa414a9272016-01-01T00:00:00Zhttps://www.dovepress.com/lipegfilgrastim-in-the-management-of-chemotherapy-induced-neutropenia--peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Roberto Guariglia,1 Maria Carmen Martorelli,1 Rosa Lerose,2 Donatella Telesca,2 Maria Rita Milella,2 Pellegrino Musto3 1Unit of Hematology and Stem Cell Transplantation, 2Pharmacy Service, 3Scientific Direction, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza, Italy Abstract: Neutropenia and febrile neutropenia (FN) are frequent and potentially fatal toxicities of myelosuppressive anticancer treatments. The introduction of granulocyte colony-stimulating factors (G-CSFs) in clinical practice has remarkably reduced the duration and severity of neutropenia, as well as the incidence of FN, thus allowing the administration of chemotherapeutic agents at the optimal dose and time with lower risk. The current scenario of G-CSFs in Europe includes filgrastim, lenograstim, some G-CSF biosimilars, and pegfilgrastim. Recently, a novel long-acting G-CSF, lipegfilgrastim, became available. Lipegfilgrastim is a glycopegylated G-CSF, alternative to pegfilgrastim, and has shown in randomized trials, to be equivalent to pegfilgrastim in reducing the incidence of severe neutropenia and FN in patients with breast cancer receiving chemotherapy, with a similar safety profile. Furthermore, lipegfilgrastim was more effective than the placebo in reducing the incidence of severe neutropenia, its duration, and time to absolute neutrophil count recovery, in patients with non-small cell lung cancer receiving myelosuppressive therapy. Although the number of studies currently published is still limited, lipegfilgrastim seems to be a promising drug in the management of chemotherapy-induced neutropenia. Keywords: neutropenia, febrile neutropenia, granulocyte colony-stimulating factors, G-CSF, pegfilgrastim, lipegfilgrastimGuariglia RMartorelli MCLerose RTelesca DMilella MRMusto PDove Medical PressarticleChemotherapy-induced neutropeniafebrile neutropeniagranulocyte colony stimulating factorsG-CSFpegfilgrastimlipegfilgrastim.Medicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2016, Iss Issue 1, Pp 1-8 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Chemotherapy-induced neutropenia febrile neutropenia granulocyte colony stimulating factors G-CSF pegfilgrastim lipegfilgrastim. Medicine (General) R5-920
spellingShingle	Chemotherapy-induced neutropenia febrile neutropenia granulocyte colony stimulating factors G-CSF pegfilgrastim lipegfilgrastim. Medicine (General) R5-920 Guariglia R Martorelli MC Lerose R Telesca D Milella MR Musto P Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
description	Roberto Guariglia,1 Maria Carmen Martorelli,1 Rosa Lerose,2 Donatella Telesca,2 Maria Rita Milella,2 Pellegrino Musto3 1Unit of Hematology and Stem Cell Transplantation, 2Pharmacy Service, 3Scientific Direction, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza, Italy Abstract: Neutropenia and febrile neutropenia (FN) are frequent and potentially fatal toxicities of myelosuppressive anticancer treatments. The introduction of granulocyte colony-stimulating factors (G-CSFs) in clinical practice has remarkably reduced the duration and severity of neutropenia, as well as the incidence of FN, thus allowing the administration of chemotherapeutic agents at the optimal dose and time with lower risk. The current scenario of G-CSFs in Europe includes filgrastim, lenograstim, some G-CSF biosimilars, and pegfilgrastim. Recently, a novel long-acting G-CSF, lipegfilgrastim, became available. Lipegfilgrastim is a glycopegylated G-CSF, alternative to pegfilgrastim, and has shown in randomized trials, to be equivalent to pegfilgrastim in reducing the incidence of severe neutropenia and FN in patients with breast cancer receiving chemotherapy, with a similar safety profile. Furthermore, lipegfilgrastim was more effective than the placebo in reducing the incidence of severe neutropenia, its duration, and time to absolute neutrophil count recovery, in patients with non-small cell lung cancer receiving myelosuppressive therapy. Although the number of studies currently published is still limited, lipegfilgrastim seems to be a promising drug in the management of chemotherapy-induced neutropenia. Keywords: neutropenia, febrile neutropenia, granulocyte colony-stimulating factors, G-CSF, pegfilgrastim, lipegfilgrastim
format	article
author	Guariglia R Martorelli MC Lerose R Telesca D Milella MR Musto P
author_facet	Guariglia R Martorelli MC Lerose R Telesca D Milella MR Musto P
author_sort	Guariglia R
title	Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
title_short	Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
title_full	Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
title_fullStr	Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
title_full_unstemmed	Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
title_sort	lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/1d9aa841d64a4175b0b8db2aa414a927
work_keys_str_mv	AT guarigliar lipegfilgrastiminthemanagementofchemotherapyinducedneutropeniaofcancerpatients AT martorellimc lipegfilgrastiminthemanagementofchemotherapyinducedneutropeniaofcancerpatients AT leroser lipegfilgrastiminthemanagementofchemotherapyinducedneutropeniaofcancerpatients AT telescad lipegfilgrastiminthemanagementofchemotherapyinducedneutropeniaofcancerpatients AT milellamr lipegfilgrastiminthemanagementofchemotherapyinducedneutropeniaofcancerpatients AT mustop lipegfilgrastiminthemanagementofchemotherapyinducedneutropeniaofcancerpatients
_version_	1718399920819404800

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients

Ejemplares similares